Colorectal Cancer Metastatic
Conditions
Keywords
Colorectal cancer, Tocotrienol, Natural killer cells, Circulating tumor DNA
Brief summary
This double blind, randomized phase II trial will investigate whether the addition of tocotrienol will improve the effect and lower the toxicity of standard chemotherapy and bevacizumab. Half of the patients will receive tocotrienol and the other half placebo. Treatment is planned for a period of maximum six months and will be discontinued earlier in case of progression or unacceptable toxicity.
Interventions
DRUGFluorouracil
2800 mg/m2 iv
DRUGCalcium folinate
400 mg/m2 iv
DRUGOxaliplatin
85 mg/m2 iv
DRUGBevacizumab
5 mg/kg OR 7.5 mg/kg iv
DRUGCapecitabine
2000 mg/m2 orally daily for two weeks
DIETARY_SUPPLEMENTTocotrienol
300 mg orally x 3 daily
OTHERPlacebo
Placebo orally x 3 daily
Sponsors
Vejle Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histopathologically verified adenocarcinoma of the colon or rectum * Metastatic disease * Planned treatment with FOLFOX or capecitabine combined with bevacizumab * Evaluable disease according to RECIST 1.1 * Performance status 0-2 * Expected survival ≥ 3 months * Patient acceptance to collection of blood samples for translational research * Age ≥ 18 years * Contraception during and 6 months after last dose for women of childbearing potential (less than one year amenorrhea and not undergone hysterectomy, bilateral salpingectomy or bilateral oophorectomy) and for male patients with a fertile partner. Hormonal contraception, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, or sexual abstinence is accepted. * Adequate bone marrow function, liver function, and renal function (within 7 days prior to inclusion): * WBC ≥ 3.0 x 109/l or neutrophils (ANC) ≥ 1.5 x 10\^9/l * Platelet count ≥ 100 x 10\^9/l * Hemoglobin ≥ 6.0 mmol/l * Serum bilirubin ≤ 2.0 x ULN * Serum transaminase ≤ 2.5 x ULN * Serum creatinine ≤ 1.5 ULN * Urine dipstick for protein ≤ 2+, if the dipstick shows protein ≥ 2+, 24 hour urine testing must be performed and show protein contents ≤ 1g. * Written and orally informed consent
Exclusion criteria
* Other active malignant disease within 5 years prior to inclusion in the study. * Other experimental therapy within 28 days prior to treatment initiation. * Underlying medical disease not adequately treated. * Surgery, including open biopsy, within 4 weeks prior to first dose of bevacizumab. * Cerebral vascular attack, transient ischemic attack or subarachnoid hemorrhage within six months before start of treatment * Bleeding tumor * Pregnant or breastfeeding women * Fertile patients not willing to use effective methods of contraception during treatment and for six months after end of treatment. * Hypersensitivity to one or more active substances or auxiliary substances
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The rate of progression free patients at six months | Six months after enrollment of the last patient |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to first serious adverse event according to CTCAE 5.0 | Six months after enrollment of the last patient | CTCAE=Common Terminology Criteria for Adverse Events |
| Response rate as measured by RECIST 1.1 | Six months after enrollment of the last patient | RECIST=Response evaluation criteria in solid tumors |
| Overall survival | 12 months after enrollment of the last patient | — |
Countries
Denmark
Contacts
STUDY_CHAIRTorben F Hansen, MD, PhD
Department of Oncology, Vejle Hospital - University Hospital of Southern Denmark
Outcome results
None listed